MND / ALS
Researchers have shown "top-line" results from the phase 2b trial of low dose Interleukin-2 (ld IL2) in MND patients. The MIROCALS (Modifying Immune Response and Outcomes in ALS) Trial Consortium has announced the findings at an online audience by Dr Gilbert Bensimon, Centre Hospitalier Universitaire de Nîmes, on the opening day of the 33rd International Symposium [...]
Findings prompt MND Association to launch campaign calling on government to undertake a full review of carers’ assessments
A new clinic has been created to offer additional dysphagia interventions
Risk of dementia is twice as high as general population, rising to up to 15 times as high for MND, shocking new study reveals
Calls made as research reveals diagnosis of a genetic cause of ALS in hundreds of people could be missed due to rules around testing
Motor neurone disease (MND) affects up to 5,000 adults in the UK at any one time
New research reveals the potential of the drug terazosin in supporting those with motor neuron disease
Thousands of people could be living without diagnosis of the motor neuron disease, research reveals
The MND Collaborative Partnership brings together patients, charities, government bodies and academia
Research could help pave the way to new diagnostic approaches and treatments for this group of conditions
